3- (4- (3- chlorophenyl)- 1- ethyl- 7- methyl- 2- oxo- 1,2- dihydro- 1,8- naphthyridin- 3- yl)propanoic acid

01/01/2012 - "Overall, these findings suggest that ASP3258 has therapeutic potential for treating neutrophilic inflammation such as COPD, partly through direct inhibition of neutrophil activation as well as possibly through inhibition of the TNF-α-mediated pathway."
05/20/2011 - "These findings suggest that ASP3258 has therapeutic potential for treating COPD not only through inhibition of pulmonary cellular accumulation but also by preventing lung structural alterations initiated by repeated cigarette smoke exposure. "
01/01/2015 - "The potent and selective phosphodiesterase 4 inhibitor ASP3258 is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease (COPD). "
05/20/2011 - "Here, we investigated the effect of ASP3258 on cigarette smoke exposure-induced lung injury in guinea pigs, a well-defined model for chronic obstructive pulmonary disease (COPD). "
02/01/2015 - "The potent phosphodiesterase 4 inhibitor ASP3258 contains a carboxylic acid moiety and a naphthyridine ring and is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease. "

01/01/2015 - "The potent and selective phosphodiesterase 4 inhibitor ASP3258 is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease (COPD). "
01/01/2012 - "These results suggest that ASP3258 is an attractive PDE4 inhibitor for treating chronic eosinophilic airway inflammation due to asthma."
01/01/2012 - "ASP3258's potent inhibition of antigen-induced bronchoconstriction and airway hyperresponsiveness, two characteristic symptoms of bronchial asthma, suggests that this compound will be useful in treating asthma."
02/01/2015 - "The potent phosphodiesterase 4 inhibitor ASP3258 contains a carboxylic acid moiety and a naphthyridine ring and is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease. "

01/01/2012 - "Overall, these findings suggest that ASP3258 has therapeutic potential for treating neutrophilic inflammation such as COPD, partly through direct inhibition of neutrophil activation as well as possibly through inhibition of the TNF-α-mediated pathway."
01/01/2012 - "Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation."
06/01/2011 - "Although ASP3258 (3mg/kg) inhibited airway inflammation completely, it had no emetic activity. "
01/01/2012 - "These results suggest that ASP3258 is an attractive PDE4 inhibitor for treating chronic eosinophilic airway inflammation due to asthma."

01/01/2012 - "Although PDE4 inhibitors induce emesis by mimicking the pharmacological action of an α(2)-adrenoceptor antagonist, repeated administration of ASP3258 (3 mg/kg) had no such inhibitory effect on rats anesthetized with α(2) - adrenoceptor agonist. "
06/01/2011 - "However, orally administered roflumilast (3mg/kg) and cilomilast (10mg/kg), but not ASP3258 (3mg/kg), inhibited α(2)-adrenoceptor agonist-induced anesthesia in rats and induced emesis in ferrets. "

05/20/2011 - "Here, we investigated the effect of ASP3258 on cigarette smoke exposure-induced lung injury in guinea pigs, a well-defined model for chronic obstructive pulmonary disease (COPD). "
05/20/2011 - "Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs."